ADVATE Drug Profile

Summary for Tradename: ADVATE

High Confidence Patents:	27
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for ADVATE

Recent Clinical Trials for ADVATE

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Runhui WU	PHASE4
Sanofi	Phase 1
Chulalongkorn University	Phase 4

See all ADVATE clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ADVATE Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ADVATE Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Takeda Pharmaceuticals U.s.a., Inc.	ADVATE	antihemophilic factor (recombinant), plasma/albumin free method	For Injection	125063	5,633,150	2014-05-27	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	ADVATE	antihemophilic factor (recombinant), plasma/albumin free method	For Injection	125063	5,733,873	2015-03-31	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	ADVATE	antihemophilic factor (recombinant), plasma/albumin free method	For Injection	125063	5,972,885	2015-12-21	DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	ADVATE	antihemophilic factor (recombinant), plasma/albumin free method	For Injection	125063	6,037,508	2018-12-11	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for ADVATE Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Takeda Pharmaceuticals U.s.a., Inc.	ADVATE	antihemophilic factor (recombinant), plasma/albumin free method	For Injection	125063	11,004,545	2038-10-15	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	ADVATE	antihemophilic factor (recombinant), plasma/albumin free method	For Injection	125063	6,248,363	2019-11-23	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	ADVATE	antihemophilic factor (recombinant), plasma/albumin free method	For Injection	125063	6,309,663	2019-08-17	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	ADVATE	antihemophilic factor (recombinant), plasma/albumin free method	For Injection	125063	6,720,001	2019-10-18	Patent claims search

International Patents for ADVATE

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2011066457
Norway	20060528
South Korea	20090073222
South Korea	101445409

Market Dynamics and Financial Trajectory for ADVATE

Last updated: February 20, 2026

What is ADVATE?

ADVATE (Antihemophilic Factor VIII Recombinant, Human-Cell Derived) is a recombinant clotting factor VIII used for hemophilia A treatment. Approved by the FDA in 2014, it is produced by Baxalta, now part of Takeda Pharmaceuticals. ADVATE's key differentiator lies in its recombinant production process, reducing the risk of viral transmission compared to plasma-derived products.

Market Size and Growth

The global hemophilia A market was valued at approximately USD 10.2 billion in 2021. It is projected to grow at a compound annual growth rate (CAGR) of 6.7% through 2028, reaching over USD 16 billion. The expansion arises from increased diagnosis, rising awareness, and the ongoing adoption of recombinant therapies.

Key Factors Influencing Market Dynamics:

• Increasing diagnosis rates: Rising awareness and improved screening methods have increased identified cases.

• Technological advances: Innovations in factor VIII formulations, such as extended half-life (EHL) products, impact patient adherence and treatment costs.

• Pricing and reimbursement policies: Reimbursement frameworks influence market penetration, especially in healthcare systems with tight budgets.

• Introduction of biosimilars: Entry of biosimilar products exerts downward pressure on prices, influencing revenue streams for original products like ADVATE.

Competitive Landscape

ADVATE competes with:

• Eloctate (Bioverativ / Biogen): An EHL recombinant factor VIII with extended dosing interval.
• Afstyla (SHL) Bioverativ: Another EHL product with a unique single-chain design.
• Biosimilars: Emerging players such as Sobi's Refixia (non-ADVATE recombinant).

In 2021, Takeda's revenues from plasma-derived and recombinant factor VIII products totaled USD 842 million, with ADVATE comprising an estimated 65-70% of recombinant factor VIII sales.

Financial Trajectory

Revenue Trends

• 2020: Revenue of approximately USD 535 million for ADVATE, representing a decline of 4% from 2019 due to pricing pressures and market saturation.
• 2021: Revenue increased to USD 560 million, driven by new geographic markets and improved access.

Pricing Dynamics

• The average annual treatment cost per patient for ADVATE ranges from USD 200,000 to USD 300,000.
• Market pressure leads to price reductions of 2-4% annually in some regions, mainly driven by biosimilar competition.
• Extended half-life products command 15-20% higher prices but may reduce overall treatment frequency.

Growth Drivers & Risks

• Drivers:
  • New indications leading to broader use.
  • Adoption in emerging markets.
  • Innovations in delivery, such as subcutaneous options.
• Risks:
  • Competition from biosimilars reducing prices.
  • Pricing reforms in major markets like Europe and the U.S.
  • Patent expiration timelines for ADVATE, projected around 2026–2028, opening market for biosimilars.

Pipeline and Future Outlook

Takeda is investing in next-generation products, including longer-lasting factor VIII complexes and gene therapy options. Gene therapy candidates, like BioMarin's valoctocogene roxaparvovec, could disrupt the recombinant factor VIII market once commercially viable.

Advancements in prophylactic regimens and immune tolerance induction may influence revenue distribution. The adoption of personalized treatment plans based on pharmacokinetics (PK) modeling can optimize costs and improve outcomes.

Regulatory and Policy Impact

Regulatory agencies are emphasizing cost-effectiveness. The U.S. has initiated policies to promote biosimilars, which could result in discounts of 20-40%. European countries, especially the UK, Germany, and France, are also implementing policies favoring biosimilar substitution.

Key Financial Data Summary

Year	Revenue (USD Millions)	Growth Rate	Market Share (Estimated)
2019	560	-	70%
2020	535	-4.3%	65%
2021	560	4.7%	68%

Summary

ADVATE’s market is shaped by recombinant therapy adoption, biosimilar competition, and regulatory policies promoting cost savings. Revenues have shown stability but face downward pressures from biosimilars and price reforms. Innovations like extended half-life products and gene therapies present growth opportunities, although they threaten ADVATE’s market share.

Key Takeaways

• ADVATE remains a dominant recombinant factor VIII in hemophilia A, with revenues around USD 560 million in 2021.
• Market growth is driven by increased diagnosis, regional expansion, and technological innovations.
• Biosimilar competition and pricing reforms are pressure points, with patent expiries around 2026–2028.
• Future growth hinges on pipeline advancements, including gene therapies, and strategic market positioning.
• Cost management and regulatory shifts necessitate ongoing adaptation for sustaining revenues.

FAQs

1. When is ADVATE’s patent set to expire?
The primary patents for ADVATE are expected to expire between 2026 and 2028, opening the market to biosimilars.

2. How does ADVATE compare price-wise with biosimilars?
Biosimilars typically undercut branded products by 20-40%, pressuring ADVATE’s revenue margins.

3. What is the impact of gene therapy?
Gene therapies like BioMarin’s valoctocogene roxaparvovec have the potential to replace repeated factor VIII infusions, threatening traditional recombinant therapies’ market share.

4. Are there geographic differences in ADVATE’s market?
Yes. U.S. markets generate most revenue, but emerging markets show growth potential due to increased diagnosis and access.

5. How do innovations in extended half-life products influence revenue?
They tend to generate higher prices and reduce treatment frequency, offering growth but also introducing competitive pressure from newer formulations.

---

References

[1] Grand View Research. Hemophilia A Market Size, Share & Trends Analysis. 2022.
[2] Takeda Annual Reports. 2019–2021.
[3] U.S. Food and Drug Administration. Summary of safety and effectiveness data for ADVATE. 2014.
[4] IQVIA. Global Hemophilia Market Report. 2021.
[5] European Medicines Agency. Biosimilar guidelines and market impact assessments. 2021.